-
公开(公告)号:US12115079B2
公开(公告)日:2024-10-15
申请号:US17600259
申请日:2020-04-15
发明人: Patrick Peter Bosch
CPC分类号: A61F2/3609 , A61F2/32 , A61F2002/30062 , A61F2002/30462 , A61F2002/30566 , A61F2002/3233
摘要: Hip tethering devices comprise a femoral implant including a housing that anchors the femoral implant to the femur, at least one spring, and a slider, such that the slider can move relative to the housing via compression and expansion of the at least one spring. A tether has a first end that anchors to the acetabulum, the tether passes through the femoral head, and a second end couples to the slider of the femoral implant, such that the tether spans across the patient's hip joint and relative motion between the slider and the housing allows a limited degree of separation of the femoral head from the acetabulum, while the at least one spring applies a variable tension load to the tether that resists separation of the femoral head from the acetabulum.
-
公开(公告)号:US20240336663A1
公开(公告)日:2024-10-10
申请号:US18579170
申请日:2022-07-15
发明人: Samira KIANI , Tahere MOKHTARI
IPC分类号: C07K14/435 , A61K38/00 , A61K48/00 , A61P29/00 , C12N15/86
CPC分类号: C07K14/435 , A61K48/005 , A61P29/00 , C12N15/86 , A61K38/00 , C07K2319/81 , C12N2750/14143
摘要: A non-naturally occurring zinc finger protein, wherein the zinc finger protein specifically binds to the promoter region of the Myd88 gene, is provided, as well as related polynucleotides, vectors, cells, and pharmaceutical compositions. In some aspects, the zinc finger protein comprises one or more repressors. Pharmaceutical compositions comprising a pharmaceutically acceptable carrier and: (A) one or more RNA interference (RNAi) agents targeting the Myd88 gene, or related polynucleotides, vectors, or cells: (B) a target antigen or a polynucleotide encoding the target antigen; and (C) a gene therapy are also provided. Methods for ameliorating inflammation and/or immune response in a subject using the RNAi agents, zinc finger protein, polynucleotides, vectors, cells, and pharmaceutical compositions also are provided.
-
公开(公告)号:US20240335408A1
公开(公告)日:2024-10-10
申请号:US18619902
申请日:2024-03-28
发明人: Anthony J. Kanai , Irina Zabbarova , Youko Ikeda
IPC分类号: A61K31/197 , A61K31/192 , A61K31/47 , A61K31/506 , A61K31/5377 , A61K45/06
CPC分类号: A61K31/197 , A61K31/192 , A61K31/47 , A61K31/506 , A61K31/5377 , A61K45/06
摘要: Provided herein are methods of treating cancer and fibrosis in a patient. The cancer may be prostate cancer. The fibrosis may be cystitis arising from a cancer therapy, such as from treatment of prostate cancer. The methods involve activation of senescent cells, such as senescent cancer cells with a soluble guanylate cyclase activator. The treatment with the soluble guanylate cyclase activator may be a primary therapy or an adjuvant therapy to a primary cancer therapy such as a chemotherapy or radiation therapy. The treatment may be administered after completion of a primary cancer therapy.
-
公开(公告)号:US20240335372A1
公开(公告)日:2024-10-10
申请号:US18294226
申请日:2022-08-02
CPC分类号: A61K9/0036 , A61K9/7007 , A61P31/12
摘要: Provided herein are stable, bioerodible films containing active ingredients, such as antimicrobial composition, antiviral compositions, antiretroviral compositions, and/or contraceptive compositions for intravaginal placement to provide prophylaxis against viral infections and contraception.
-
公开(公告)号:US12110316B2
公开(公告)日:2024-10-08
申请号:US17287480
申请日:2019-10-18
发明人: Alan H. Wells
CPC分类号: C07K14/522 , C12N9/6491 , A61K38/00
摘要: Recombinant C-X-C motif chemokine ligand (CXCL) peptides modified to introduce a cleavage site for a protease, such as a protease activated during an inflammatory response, are described. The CXCL peptides have the capacity to activate CXCR3 until being cleaved by the protease. Proteolytic cleavage of the CXCL peptide minimizes the pro-inflammatory response and inhibits the development of fibrosis.
-
公开(公告)号:US20240325537A1
公开(公告)日:2024-10-03
申请号:US18580954
申请日:2022-07-19
发明人: Greg M. Delgoffe , Ronal Peralta
IPC分类号: A61K39/00 , A61K45/06 , A61P35/00 , C07K14/725 , C12N5/0783 , C12N15/113
CPC分类号: A61K39/464412 , A61K39/4611 , A61K39/4644 , A61K39/464404 , A61K39/464406 , A61K39/464417 , A61K39/464424 , A61K39/464466 , A61K39/464468 , A61K39/46447 , A61K39/464474 , A61K39/464482 , A61K39/464494 , A61K45/06 , A61P35/00 , C07K14/7051 , C12N5/0636 , C12N15/113 , C12N2310/14 , C12N2310/20 , C12N2310/531 , C12N2501/2302 , C12N2510/00
摘要: The present disclosure provides compositions, including modified peripheral blood mononuclear cells (PBMCs) with reduced expression of Slc16a11 and/or reduced activity of MCT11. Also provided are siRNAs and gRNAs targeting Slc16a11. Methods of using the disclosed compositions in the treatment of cancer are also provided.
-
公开(公告)号:US20240307493A1
公开(公告)日:2024-09-19
申请号:US18738964
申请日:2024-06-10
发明人: Binfeng Lu , Runzi Sun
IPC分类号: A61K38/20 , A61K39/395 , A61P35/00
CPC分类号: A61K38/20 , A61K39/3955 , A61P35/00
摘要: The present disclosure relates to the methods of preventing and/or treating cancer including administering IL33 and anti-AREG antibodies or fragments thereof to a subject in need thereof. The present disclosure further provides compositions and kits for performing such methods.
-
公开(公告)号:US20240304828A1
公开(公告)日:2024-09-12
申请号:US18654149
申请日:2024-05-03
发明人: Prashant N. Kumta , Prasad P. Patel , Moni K. Datta , Oleg Velikokhatnyi , Prashanth J. Hanumantha , Ramalinga Kuruba , Shrinath Ghadge
IPC分类号: H01M4/90 , B01J27/135 , B82Y30/00 , H01M4/88 , H01M8/08 , H01M8/1018 , H01M8/1233
CPC分类号: H01M4/9016 , H01M4/881 , H01M4/8825 , H01M8/08 , H01M8/1018 , H01M8/1233 , B01J27/135 , B82Y30/00 , Y02E60/50
摘要: The invention provides noble metal-free electro-catalyst compositions for use in acidic media, e.g., acidic electrolyte. The noble metal-free electro-catalyst compositions include non-noble metal absent of noble metal. The non-noble metal is non-noble metal oxide, and typically in the form of any configuration of a solid or hollow nano-material, e.g., nano-particles, a nanocrystalline thin film, nanorods, nanoshells, nanoflakes, nanotubes, nanoplates, nanospheres and nanowhiskers or combinations of myriad nanoscale architecture embodiments. Optionally, the noble metal-free electro-catalyst compositions include dopant, such as, but not limited to halogen. Acidic media includes oxygen reduction reaction (ORR) in proton exchange membrane (PEM) fuel cells, and direct methanol fuel cells and oxygen evolution reaction (OER) in PEM-based water electrolysis and metal air batteries, and hydrogen generation from solar energy and electricity-driven water splitting.
-
公开(公告)号:US20240299599A1
公开(公告)日:2024-09-12
申请号:US18515076
申请日:2023-11-20
发明人: Dexing ZENG , Lingyi SUN , Yongkang GAI
IPC分类号: A61K51/08 , A61K9/51 , A61K47/68 , A61K51/10 , C07D255/02 , C07D257/02 , C07K7/06 , C07K7/64 , C07K16/30 , G01N33/50 , G01N33/60
CPC分类号: A61K51/082 , A61K9/51 , A61K47/6893 , A61K51/1027 , C07D255/02 , C07D257/02 , C07K7/06 , C07K7/64 , C07K16/30 , G01N33/5008 , G01N33/60 , C07K2319/00
摘要: The present invention provides a multivalent compound for targeted molecular imaging and/or targeted drug delivery, wherein two components or targeting molecules each interacts with one or more biomarkers on a cell. The present invention further provides a multifunctional chelator to combine the targeting molecules. The present invention also provides an in vitro high-throughput screening assay to determine the length of the spacer molecules. The present invention also relates to compounds/probes, kits and methods for use in targeted molecular imaging and/or targeted drug delivery.
-
公开(公告)号:US20240299475A1
公开(公告)日:2024-09-12
申请号:US18673024
申请日:2024-05-23
CPC分类号: A61K35/76 , A61K9/0019 , A61K9/0073 , A61P31/06
摘要: Disclosed are pharmaceutical compositions comprising a combination of five or more phages and a pharmaceutically acceptable carrier, as well as methods of treating, reducing, or preventing a disease caused by Mycobacterium tuberculosis in a mammal, methods of treating an antibiotic resistant infection in a mammal, and methods of treating, reducing, or preventing activation of a latent disease caused by M. tuberculosis.
-
-
-
-
-
-
-
-
-